These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8115667)

  • 1. Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism.
    Finali G; Piccirilli M; Piccinin GL
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jan; 18(1):115-28. PubMed ID: 8115667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment.
    Portin R; Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():135-44. PubMed ID: 6428146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
    Knoll J
    J Neural Transm Suppl; 1993; 40():69-91. PubMed ID: 8294902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients.
    Streifler M; Rabey MJ
    J Neural Transm Suppl; 1983; 19():265-72. PubMed ID: 6421992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive effects of L-deprenyl in Alzheimer's disease.
    Tariot PN; Sunderland T; Weingartner H; Murphy DL; Welkowitz JA; Thompson K; Cohen RM
    Psychopharmacology (Berl); 1987; 91(4):489-95. PubMed ID: 3108930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients.
    Finali G; Piccirilli M; Oliani C; Piccinin GL
    Clin Neuropharmacol; 1991 Dec; 14(6):523-36. PubMed ID: 1773423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group.
    Ital J Neurol Sci; 1992 Dec; 13(9):735-9. PubMed ID: 1362394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J
    J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
    Lander CM; Lees A; Stern G
    Clin Exp Neurol; 1979; 16():197-203. PubMed ID: 121706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.
    Cedarbaum JM; Silvestri M; Clark M; Harts A; Kutt H
    Clin Neuropharmacol; 1990 Feb; 13(1):29-35. PubMed ID: 2106391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.
    Piccinin GL; Finali G; Piccirilli M
    Clin Neuropharmacol; 1990 Apr; 13(2):147-63. PubMed ID: 2109658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter trial of L-Deprenyl in Parkinson disease.
    Ruggieri S; Denaro A; Meco G; Carta A; Stocchi F; Agnoli A
    Ital J Neurol Sci; 1986 Feb; 7(1):133-7. PubMed ID: 3082793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
    Przuntek H; Kuhn W
    J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deprenyl in Parkinson disease.
    Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB
    Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memory for spatial location is affected in Parkinson's disease.
    Pillon B; Ertle S; Deweer B; Sarazin M; Agid Y; Dubois B
    Neuropsychologia; 1996 Jan; 34(1):77-85. PubMed ID: 8852695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.